Publication | Open Access

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

MedicineCancer ManagementPhase IiiPathologyCancer TreatmentOpen-label StudyOncologyRadiation OncologyLung Cancer